SRZN Surrozen Forecast, Technical & Fundamental Analysis
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues... Show more
SRZN is expected to report earnings to fall 88.93% to -128 cents per share on August 06
Q2'26
Est.
$-1.29
Q1'26
Missed
by $10.66
Q4'25
Missed
by $18.10
Q2'25
Beat
by $3.16
Q1'25
Missed
by $6.34
The last earnings report on May 06 showed earnings per share of -1164 cents, missing the estimate of -99 cents. With 182.29K shares outstanding, the current market capitalization sits at 263.90M.
A.I.dvisor indicates that over the last year, SRZN has been loosely correlated with VIR. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if SRZN jumps, then VIR could also see price increases.
SRZN in +7.27% Uptrend, advancing for three consecutive days on June 23, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SRZN advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SRZN's RSI Indicator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
SRZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 192 cases where SRZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRZN as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for SRZN turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.219) is normal, around the industry mean (22.885). P/E Ratio (0.000) is within average values for comparable stocks, (37.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.508). SRZN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (28.249) is also within normal values, averaging (434.181).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SRZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
